Related Experiment Videos
Azathioprine-induced warfarin resistance
Sara R Vazquez1, Matthew T Rondina, Robert C Pendleton
1UDepartment of Pharmacy Services, University Thrombosis Service, University of Utah, Salt Lake City, UT 84108, USA. sara.vazquez@hsc.utah.edu
The Annals of Pharmacotherapy
|May 29, 2008
Summary
Azathioprine can cause warfarin resistance, requiring higher warfarin doses and close monitoring. This drug interaction necessitates careful management to ensure patient safety and effective anticoagulation.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Interactions
Background:
- Warfarin is a common anticoagulant, and azathioprine is an immunosuppressive drug.
- Drug interactions can significantly alter medication efficacy and patient safety.
Observation:
- A patient on warfarin experienced significant resistance after initiating azathioprine, requiring a nearly threefold increase in warfarin dosage.
- Upon reducing the azathioprine dose, warfarin requirements decreased, indicating a direct interaction.
Findings:
- Azathioprine is identified as a probable cause of warfarin resistance.
- Literature review confirms multiple cases of azathioprine and 6-mercaptopurine-induced warfarin resistance.
- The interaction appears rapid in onset and offset, with dose-dependent effects on warfarin requirements.
Implications:
- Healthcare providers must anticipate and manage azathioprine-induced warfarin resistance.
- Close international normalized ratio (INR) monitoring and warfarin dose adjustments are crucial for patients on both medications.
- Understanding this interaction is vital for preventing thrombotic events in patients requiring anticoagulation and immunosuppression.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...